Numerical Simulations Reproduce Field Observations Showing Transient Weakening During Shear Zone Formation by Diffusional Hydrogen Influx and H2O Inflow

Exposures on Holsnøy island (Bergen Arcs, Norway) indicate fluid infiltration through fractures into a dry, metastable granulite, which triggered a kinetically delayed eclogitization, a transient weakening during fluid-rock interaction, and formation of shear zones that widened during shearing. It remains unclear whether the effects of grain boundary-assisted aqueous fluid inflow on the duration of granulite hydration were influenced by a diffusional hydrogen influx accompanying the fluid inflow. To better estimate the fluid infiltration efficiencies and the parameter interdependencies, a 1D numerical model of a viscous shear zone is utilized and validated using measured mineral phase abundance distributions and H2O-contents in nominally anhydrous minerals of the original granulite assemblage to constrain the hydration by aqueous fluid inflow and diffusional hydrogen influx, respectively. Both hydrations are described with a diffusion equation and affect the effective viscosity. Shear zone kinematics are constrained by the observed shear strain and thickness. The model fits the phase abundance and H2O-content profiles if the effective hydrogen diffusivity is approximately one order of magnitude higher than the diffusivity for aqueous fluid inflow. The observed shear zone thickness is reproduced if the viscosity ratio between dry granulite and deforming, reequilibrating eclogite is ∼104 and that between dry granulite and hydrated granulite is ∼102. The results suggest shear velocities <10−2 cm/a, hydrogen diffusivities of ∼10−13±1 m2/s, and a shearing duration of <10 years. This study successfully links and validates field data to a shear zone model and highlights the importance of hydrogen diffusion for shear zone widening and eclogitization

Numerical Simulations Reproduce Field Observations Showing Transient Weakening During Shear Zone Formation by Diffusional Hydrogen Influx and H₂O Inflow

Exposures on Holsnøy island (Bergen Arcs, Norway) indicate fluid infiltration through fractures into a dry, metastable granulite, which triggered a kinetically delayed eclogitization, a transient weakening during fluid-rock interaction, and formation of shear zones that widened during shearing. It remains unclear whether the effects of grain boundary-assisted aqueous fluid inflow on the duration of granulite hydration were influenced by a diffusional hydrogen influx accompanying the fluid inflow. To better estimate the fluid infiltration efficiencies and the parameter interdependencies, a 1D numerical model of a viscous shear zone is utilized and validated using measured mineral phase abundance distributions and H2O-contents in nominally anhydrous minerals of the original granulite assemblage to constrain the hydration by aqueous fluid inflow and diffusional hydrogen influx, respectively. Both hydrations are described with a diffusion equation and affect the effective viscosity. Shear zone kinematics are constrained by the observed shear strain and thickness. The model fits the phase abundance and H2O-content profiles if the effective hydrogen diffusivity is approximately one order of magnitude higher than the diffusivity for aqueous fluid inflow. The observed shear zone thickness is reproduced if the viscosity ratio between dry granulite and deforming, reequilibrating eclogite is ∼104 and that between dry granulite and hydrated granulite is ∼102. The results suggest shear velocities <10−2 cm/a, hydrogen diffusivities of ∼10−13±1 m2/s, and a shearing duration of <10 years. This study successfully links and validates field data to a shear zone model and highlights the importance of hydrogen diffusion for shear zone widening and eclogitization

Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/111930/1/jth12969.pd

Hypoglycemia After Administration of Somatostatin Analog (SMS 201-995) in Metastatic Carcinoid

SMS 201-995 (Sandoz Pharmaceuticals. East Hanover NJ) is a synthetic peptide analog of native somatostatin that has been used to relieve .symptoms caused by neuroendocrine tumors. Reports have described an insulin suppressive effect of SMS 201-995 that results in elevations of blood glucose. We report a patient with a metastatic small bowel carcinoid and renal failure in whom mild symptomatic hypoglycemia occurred 30 to 60 minutes after SMS 201-995 administration. No increase in insulin or decreases in glucagon. Cortisol, or catecholamines were observed during these hypoglycemic episodes. Elevated levels of growth hormone fell gradually following SMS 201-995 administration and did not temporally correspond to the 30- to 60-minute nadir of blood glucose. However SMS 201-995 levels peaked during this 30- to 60-minute period. As clinical experience with this drug broadens, patients whose glucose control is dependent on counter-regulatory hormones should be monitored for the possibility of hypoglycemia

A gender bias habit-breaking intervention led to increased hiring of female faculty in STEMM departments

Addressing the underrepresentation of women in science is a top priority for many institutions, but the majority of efforts to increase representation of women are neither evidence-based nor rigorously assessed. One exception is the gender bias habit-breaking intervention (Carnes et al., 2015), which, in a cluster-randomized trial involving all but two departmental clusters (N = 92) in the 6 STEMM focused schools/colleges at the University of Wisconsin – Madison, led to increases in gender bias awareness and self-efficacy to promote gender equity in academic science departments. Following this initial success, the present study compares, in a preregistered analysis, hiring rates of new female faculty pre- and post-manipulation. Whereas the proportion of women hired by control departments remained stable over time, the proportion of women hired by intervention departments increased by an estimated 18 percentage points (OR = 2.23, dOR = 0.34). Though the preregistered analysis did not achieve conventional levels of statistical significance (p \u3c 0.07), our study has a hard upper limit on statistical power, as the cluster-randomized trial has a maximum sample size of 92 departmental clusters. These patterns have undeniable practical significance for the advancement of women in science, and provide promising evidence that psychological interventions can facilitate gender equity and diversity

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation

BACKGROUND: It is uncertain whether bridging anticoagulation is necessary for patients with atrial fibrillation who need an interruption in warfarin treatment for an elective operation or other elective invasive procedure. We hypothesized that forgoing bridging anticoagulation would be noninferior to bridging with low-molecular-weight heparin for the prevention of perioperative arterial thromboembolism and would be superior to bridging with respect to major bleeding. METHODS: We performed a randomized, double-blind, placebo-controlled trial in which, after perioperative interruption of warfarin therapy, patients were randomly assigned to receive bridging anticoagulation therapy with low-molecular-weight heparin (100 IU of dalteparin per kilogram of body weight) or matching placebo administered subcutaneously twice daily, from 3 days before the procedure until 24 hours before the procedure and then for 5 to 10 days after the procedure. Warfarin treatment was stopped 5 days before the procedure and was resumed within 24 hours after the procedure. Follow-up of patients continued for 30 days after the procedure. The primary outcomes were arterial thromboembolism (stroke, systemic embolism, or transient ischemic attack) and major bleeding. RESULTS: In total, 1884 patients were enrolled, with 950 assigned to receive no bridging therapy and 934 assigned to receive bridging therapy. The incidence of arterial thromboembolism was 0.4% in the no-bridging group and 0.3% in the bridging group (risk difference, 0.1 percentage points; 95% confidence interval [CI], -0.6 to 0.8; P=0.01 for noninferiority). The incidence of major bleeding was 1.3% in the no-bridging group and 3.2% in the bridging group (relative risk, 0.41; 95% CI, 0.20 to 0.78; P=0.005 for superiority). CONCLUSIONS: In patients with atrial fibrillation who had warfarin treatment interrupted for an elective operation or other elective invasive procedure, forgoing bridging anticoagulation was noninferior to perioperative bridging with low-molecular-weight heparin for the prevention of arterial thromboembolism and decreased the risk of major bleeding. (Funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health; BRIDGE ClinicalTrials.gov number, NCT00786474.)

Evolutionary patterns in sound production across fishes

Published versio

Adverse clinical sequelae after skin branding: a case series

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licens

Edoxaban: an update on the new oral direct factor Xa inhibitor.

Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with non-valvular atrial fibrillation (NVAF) and symptomatic venous thromboembolism (VTE). The ENGAGE AF-TIMI 48 study (N = 21,105; mean CHADS2 score 2.8) compared edoxaban 60 mg once daily (high-dose regimen) and edoxaban 30 mg once daily (low-dose regimen) with dose-adjusted warfarin [international normalized ratio (INR) 2.0-3.0] and found that both regimens were non-inferior to warfarin in the prevention of stroke and systemic embolism in patients with NVAF. Both edoxaban regimens also provided significant reductions in the risk of hemorrhagic stroke, cardiovascular mortality, major bleeding and intracranial bleeding. The Hokusai-VTE study (N = 8,292) in patients with symptomatic VTE had a flexible treatment duration of 3-12 months and found that following initial heparin, edoxaban 60 mg once daily was non-inferior to dose-adjusted warfarin (INR 2.0-3.0) for the prevention of recurrent VTE, and also had a significantly lower risk of bleeding events. Both studies randomized patients at moderate-to-high risk of thromboembolic events and were further designed to simulate routine clinical practice as much as possible, with edoxaban dose reduction (halving dose) at randomisation or during the study if required, a frequently monitored and well-controlled warfarin group, a well-monitored transition period at study end and a flexible treatment duration in Hokusai-VTE. Given the phase III results obtained, once-daily edoxaban may soon be a key addition to the range of antithrombotic treatment options